Brainstorm Cell reports positive interim results in ALS trial

The company's bone marrow stem cell treatment improved patients' ability to breathe and swallow, and their muscular function.

Brainstorm Cell Therapeutics Ltd. (Bulletin Board:BCLI) today announced positive interim results in its Phase I clinical trial to test the safety and efficacy of its adult stem cell treatment of Amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease). The company reports indications that the treatment improved the condition of the first six patients enrolled in the study.

The study report sent to the company stated that the patients' ability to breathe, swallow, and muscular function improved and that there were no substantial side effects. There is no cure for the lethal disease, and any improvement in patients is considered good news.

Brainstorm Cell's treatment is extremely innovative, as it is based on injections of bone marrow stem cells into the brain tissue so cells will differentiate into nerve cells and excrete the enzymes that are missing in ALS patients.

The trial does not have a control group, nor are there any accurate markers to assess the condition of ALS patients. The assessment of improvement in the condition of the participating patients is based on clinical observation and the patients' reports, and therefore subject to psychological influences. Since there is a risk of over-optimism, more data is necessary to assess whether the company's treatment is successful and a breakthrough in stem cell treatments.

Brainstorm Cell's NurOwn technology was developed by Professor Eldad Melamed and Professor Daniel Offen of Tel Aviv University.

Brainstorm Cell's share price closed at $0.30 in New York yesterday, giving a market cap of $37 million.

Published by Globes [online], Israel business news - - on January 17, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017